Why the study?
Following the FDA approval of subcutaneous furosemide for NYHA class II and III chronic heart failure, a summary of evidence comparing it with oral and intravenous formulations was needed.
Does subcutaneous furosemide improve decongestive therapy in adult patients with New York Heart Association class II and class III chronic heart failure compared to oral and intravenous formulations?
Does subcutaneous furosemide improve decongestive therapy in adult patients with New York Heart Association class II and class III chronic heart failure compared to oral and intravenous formulations?
Subcutaneous furosemide represents a novel approach to decongestive therapy that may facilitate the transition of heart failure management from inpatient to outpatient or home-based settings.
Furoscix, a subcutaneous pH-neutral formulation of furosemide, obtained US Food and Drug Administration approval in October 2022 for adult patients with New York Heart Association class II and class III chronic heart failure. This approval marks an anticipated potential shift in the traditional management of decongestive therapy in chronic heart failure patients from the confines of the hospital to more accessible outpatient or home-based care. In this review, we will summarize existing evidence regarding the use of subcutaneous furosemide in comparison to both oral and intravenous formulations, highlighting the demonstrable benefits of its application in both outpatient and inpatient settings, and also discuss several factors that may limit its use.
No takes yet. Share an insight, caveat, or question.
Cheikhali et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: